Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.

ABSTRACT:

Purpose

The impact of a personalized cancer treatment strategy (ie, matching patients with drugs based on specific biomarkers) is still a matter of debate.

Methods

We reviewed phase II single-agent studies (570 studies; 32,149 patients) published between January 1, 2010, and December 31, 2012 (PubMed search). Response rate (RR), progression-free survival (PFS), and overall survival (OS) were compared for arms that used a personalized strategy versus those that did not.

Results

Multivariable analysis (both weighted multiple linear regression and random effects meta-regression) demonstrated that the personalized approach, compared with a nonpersonalized approach, consistently and independently correlated with higher median RR (31% v 10.5%, respectively; P < .001) and pr

SUBMITTER: Schwaederle M 

PROVIDER: S-EPMC4737863 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature